Upcoming catalysts for AEGR include:
1) EMA CHMP recommendation for EU approval
2) Final EU approval
3) Patient Count increases to 200+ in this quarter
4) 2-1 stock split after it crosses $50/share
5) Buyout rumors and suitors will start swirling
6) Buyout itself at much higher prices.
Hard to say. Pfizer probably has the greatest need to replace their dwindling pipeline.
Don't rush to a buyout just yet as this stock can grow organically quite a bit first. Then it would be OK for a buyout at $120-$240/share.